{
  "id": 17051020,
  "title": "Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026",
  "url": "https://urgent.news/2026/10/29/biogen-to-present-new-data-across-alzheimers-disease-portfolio-at",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-29T11:09:20.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/biogen-to-present-new-data-across-alzheimers-disease-portfolio-at-ctad-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer’s disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}